Product candidates will be based on BioNTech’s proprietary mRNA technology and on Pfizer’s antigen technology. Clinical trials are expected to start in the second half of 2022
JBI-802 is a novel, oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6
The R&D centre will endeavour to bring scientifically advanced biological, biotechnology products and novel drug delivery systems
Entos will receive an initial payment of US $50 million, which includes an equity investment by Lilly
The drug is priced at Rs 2000 for a course of 40 tablets
Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal condition
Hitz shall assume new role from January 17th, 2022
After double lung transplantation, he was discharged without supplemental oxygen on the eleventh day
The brand is now available pan-India through their distribution partner
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
Subscribe To Our Newsletter & Stay Updated
